StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/3033% below fair value
$0.91−0.07 (-7.38%)

Close on Nov 20, 2026Market cap $241.49MP/E –Yield –

Autolus Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Autolus Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$232.73M. For fiscal 2025 it was -$302.61M. The highest annual figure on record is -$11.70M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$302.61M–
FY2024Dec 31, 2024-$228.35M–
FY2023Dec 31, 2023-$156.57M–
FY2022Dec 31, 2022-$123.15M–
FY2021Dec 31, 2021-$126.72M–
FY2020Dec 31, 2020-$132.44M–
FY2018Sep 30, 2018-$40.66M–
FY2017Sep 30, 2017-$19.24M–
FY2016Sep 30, 2016-$11.70M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$25.98M–
Q1 FY2026CQ1 2026Mar 31, 2026-$68.01M–
Q4 FY2025CQ4 2025Dec 31, 2025-$66.44M–
Q3 FY2025CQ3 2025Sep 30, 2025-$72.31M–
Q2 FY2025CQ2 2025Jun 30, 2025-$80.06M–
Q1 FY2025CQ1 2025Mar 31, 2025-$83.81M–
Q4 FY2024CQ4 2024Dec 31, 2024-$49.05M–
Q3 FY2024CQ3 2024Sep 30, 2024-$86.33M–
Q2 FY2024CQ2 2024Jun 30, 2024-$51.92M–
Q1 FY2024CQ1 2024Mar 31, 2024-$41.05M–
Q4 FY2023CQ4 2023Dec 31, 2023-$26.31M–
Q3 FY2023CQ3 2023Sep 30, 2023-$41.69M–
Q2 FY2023CQ2 2023Jun 30, 2023-$42.54M–
Q1 FY2023CQ1 2023Mar 31, 2023-$46.04M–
Q4 FY2022CQ4 2022Dec 31, 2022-$15.20M–
Q1 FY2021CQ1 2021Mar 31, 2021-$39.24M–
Q4 FY2020CQ4 2020Dec 31, 2020-$33.20M–
Q3 FY2020CQ3 2020Sep 30, 2020-$43.11M–
Q2 FY2020CQ2 2020Jun 30, 2020-$29.46M–
Q1 FY2020CQ1 2020Mar 31, 2020-$26.67M–

More Autolus Therapeutics figures

See a number that looks wrong?